NASDAQ:CRNX

Crinetics Pharmaceuticals Stock Forecast, Price & News

$16.73
-0.59 (-3.41 %)
(As of 04/16/2021 04:00 PM ET)
Add
Compare
Today's Range
$16.55
Now: $16.73
$17.45
50-Day Range
$14.45
MA: $16.09
$17.90
52-Week Range
$11.61
Now: $16.73
$23.70
Volume140,364 shs
Average Volume142,327 shs
Market Capitalization$552.58 million
P/E RatioN/A
Dividend YieldN/A
Beta1.24
Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 biased agonist, which is in Phase I clinical trials used for the treatment of acromegaly and neuroendocrine tumors. The company is also developing CRN01941, an oral selective nonpeptide sst2 biased agonist designed for the treatment of neuroendocrine tumors; an oral selective nonpeptide somatostatin type 5 receptor agonist for treating congenital hyperinsulinism; and an oral adrenocorticotrophic hormone antagonist for the treatment of cushing's and congenital adrenal hyperplasia diseases. Crinetics Pharmaceuticals, Inc. was founded in 2008 and is headquartered in San Diego, California.
Crinetics Pharmaceuticals logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CRNX
CUSIPN/A
CIKN/A
Phone858-450-6464
Employees68
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$1.19 million
Book Value$4.84 per share

Profitability

Net Income$-50,420,000.00

Miscellaneous

Market Cap$552.58 million
Next Earnings Date5/14/2021 (Estimated)
OptionableNot Optionable

Headlines

Crinetics Pharmaceuticals (NASDAQ:CRNX) Shares Up 5.8%
April 15, 2021 |  americanbankingnews.com
Crinetics Pharmaceuticals (NASDAQ:CRNX) Shares Down 8.1%
April 13, 2021 |  americanbankingnews.com
Insider Buys Crinetics Pharmaceuticals Shares
April 9, 2021 |  benzinga.com
Crinetics Pharmaceuticals (NASDAQ:CRNX) Shares Gap Up to $16.44
April 8, 2021 |  americanbankingnews.com
Crinetics Pharmaceuticals, Inc. to Host Earnings Call
March 30, 2021 |  finance.yahoo.com
Crinetics Pharmaceuticals (CRNX) to Release Earnings on Tuesday
March 25, 2021 |  americanbankingnews.com
See More Headlines

MarketRank

Overall MarketRank

1.78 out of 5 stars

Medical Sector

166th out of 2,024 stocks

Pharmaceutical Preparations Industry

71st out of 772 stocks

Analyst Opinion: 3.4Community Rank: 2.2Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 0.0 5 -4 -3 -2 -1 -
$16.73
-0.59 (-3.41 %)
(As of 04/16/2021 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive CRNX News and Ratings via Email

Sign-up to receive the latest news and ratings for CRNX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Crinetics Pharmaceuticals (NASDAQ:CRNX) Frequently Asked Questions

Is Crinetics Pharmaceuticals a buy right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Crinetics Pharmaceuticals in the last year. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Crinetics Pharmaceuticals stock.
View analyst ratings for Crinetics Pharmaceuticals
or view top-rated stocks.

What stocks does MarketBeat like better than Crinetics Pharmaceuticals?

Wall Street analysts have given Crinetics Pharmaceuticals a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Crinetics Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Crinetics Pharmaceuticals' next earnings date?

Crinetics Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Friday, May 14th 2021.
View our earnings forecast for Crinetics Pharmaceuticals
.

How were Crinetics Pharmaceuticals' earnings last quarter?

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) issued its earnings results on Monday, March, 29th. The company reported ($0.66) EPS for the quarter, missing the Zacks' consensus estimate of ($0.58) by $0.08.
View Crinetics Pharmaceuticals' earnings history
.

How has Crinetics Pharmaceuticals' stock been impacted by Coronavirus (COVID-19)?

Crinetics Pharmaceuticals' stock was trading at $15.50 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, CRNX stock has increased by 7.9% and is now trading at $16.73.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for CRNX?

4 brokers have issued 12-month target prices for Crinetics Pharmaceuticals' shares. Their forecasts range from $30.00 to $42.00. On average, they expect Crinetics Pharmaceuticals' share price to reach $35.00 in the next twelve months. This suggests a possible upside of 109.2% from the stock's current price.
View analysts' price targets for Crinetics Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Crinetics Pharmaceuticals' key executives?

Crinetics Pharmaceuticals' management team includes the following people:
  • Dr. R. Scott Struthers, Founder, Pres, CEO & Director (Age 59, Pay $715.39k)
  • Mr. Marc J. C. Wilson, CFO & Sec. (Age 42, Pay $450k)
  • Dr. Alan S. Krasner, Chief Medical Officer (Age 58, Pay $571.97k)
  • Dr. Yun-Fei Zhu, Founder & VP of Chemistry (Age 58)
  • Dr. Stephen F. Betz, Co-Founder & VP of Biology (Age 55)
  • Ms. Adriana Cabre, VP of HR
  • Dr. Ajay Madan DABT, Ph.D., D.A.B.T., Chief Devel. Officer (Age 53)
  • Mr. Peter Trainer BSc, MBChB, M.D., FRCP, VP of Clinical Endocrinology
  • Ms. Gina Ford M.B.A., R.Ph., RPh, VP of Corp. Strategy & Commercial Planning

What is R. Scott Struthers, Ph.D.'s approval rating as Crinetics Pharmaceuticals' CEO?

2 employees have rated Crinetics Pharmaceuticals CEO R. Scott Struthers, Ph.D. on Glassdoor.com. R. Scott Struthers, Ph.D. has an approval rating of 100% among Crinetics Pharmaceuticals' employees. This puts R. Scott Struthers, Ph.D. in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Crinetics Pharmaceuticals' key competitors?

What other stocks do shareholders of Crinetics Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Crinetics Pharmaceuticals investors own include SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), Aldeyra Therapeutics (ALDX), G1 Therapeutics (GTHX), Kura Oncology (KURA), Otonomy (OTIC), Selecta Biosciences (SELB), TG Therapeutics (TGTX), Arbutus Biopharma (ABUS) and Applied Genetic Technologies (AGTC).

When did Crinetics Pharmaceuticals IPO?

(CRNX) raised $80 million in an initial public offering (IPO) on Wednesday, July 18th 2018. The company issued 5,000,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan, Leerink Partners and Piper Jaffray served as the underwriters for the IPO.

What is Crinetics Pharmaceuticals' stock symbol?

Crinetics Pharmaceuticals trades on the NASDAQ under the ticker symbol "CRNX."

How do I buy shares of Crinetics Pharmaceuticals?

Shares of CRNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Crinetics Pharmaceuticals' stock price today?

One share of CRNX stock can currently be purchased for approximately $16.73.

How much money does Crinetics Pharmaceuticals make?

Crinetics Pharmaceuticals has a market capitalization of $552.58 million and generates $1.19 million in revenue each year. The company earns $-50,420,000.00 in net income (profit) each year or ($2.09) on an earnings per share basis.

How many employees does Crinetics Pharmaceuticals have?

Crinetics Pharmaceuticals employs 68 workers across the globe.

What is Crinetics Pharmaceuticals' official website?

The official website for Crinetics Pharmaceuticals is www.crinetics.com.

Where are Crinetics Pharmaceuticals' headquarters?

Crinetics Pharmaceuticals is headquartered at 10222 Barnes Canyon Road Building #2, San Diego CA, 92121.

How can I contact Crinetics Pharmaceuticals?

Crinetics Pharmaceuticals' mailing address is 10222 Barnes Canyon Road Building #2, San Diego CA, 92121. The company can be reached via phone at 858-450-6464 or via email at [email protected]


This page was last updated on 4/18/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.